What Full-Life Technologies does

Full-Life Technologies is a clinical-stage radiotherapeutics company founded in August 2021 and headquartered across Belgium and Shanghai, with additional operations in Germany and the United States. The company focuses on developing targeted radiopharmaceuticals using both alpha-emitting (actinium-225) and beta-emitting (lutetium-177) radionuclides conjugated to tumor-targeting ligands for oncology indications. Its discovery engine, UniRDC™, combines the Clear-X™ linker chemistry toolkit with the Res-X™ radionuclide integration toolkit, complemented by a peptide-based targeting platform acquired through the November 2022 acquisition of Focus-X Therapeutics.

The company operates a five-asset pipeline spanning prostate cancer (lead 225Ac-FL-020, currently Phase 1 with FDA Fast Track Designation), NTSR1 (FL-091, licensed to SK Biopharmaceuticals in a deal worth up to $571.5 million), SSTR2 (FL-031), c-MET (FL-261), and B7H3 (FL-801/FL-802). To secure its radionuclide supply chain and reduce dependence on third-party CDMOs, Full-Life is constructing a GMP-compliant manufacturing facility in Gembloux, Belgium, under a Belgium nuclear permit.

The business model is pre-commercial and relies on a combination of venture capital financing (~USD 200 million raised across five rounds from Chengwei Capital, Sequoia China, Prosperity7, Junson Capital, and Vivo Capital) and partnership-based monetization through licensing agreements. The SK Biopharmaceuticals transaction is the primary external revenue channel via upfront and milestone payments, with future revenue contingent on commercialization of partnered assets. Ultimate commercial value will depend on successful Phase 1 progression of 225Ac-FL-020, regulatory approval pathways, and execution of additional licensing or co-development partnerships.

Name

Full-Life Technologies

Legal name

Shanghai Full-Life Technologies Co., Ltd. (上海辐联医药科技有限公司)

Website

https://full-life.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

Full-Life Technologies is a clinical-stage radiotherapeutics company developing alpha- and beta-emitting radiopharmaceutical conjugates for solid tumors, leveraging its UniRDC™ discovery platform and an in-house GMP manufacturing facility to serve oncology patients globally.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Radiopharmaceutical development
• Radionuclide drug conjugates
• Cancer therapy pipeline
• Radiotherapy manufacturing
• Biotech drug discovery

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing & Royalty Income (Out-Licensing): Pre-commercial but secured a major out-licensing deal in July 2024: exclusive worldwide license to SK Biopharmaceuticals for FL-091 (now SKL35501/SKL35502), a NTSR1-targeting alpha-emitter RDC program, with a total deal value of $571.5 million (upfront, development and commercial milestones) plus royalties. Includes a right of first negotiation for SK Biopharmaceuticals on other selected RDC programs. Represents the company's first material revenue stream via upfront and milestone payments.
2. Future Therapeutic Product Sales: Long-term, intended commercial revenue from sales of wholly-owned RDC therapeutic products (e.g., 225Ac-FL-020 for mCRPC, 225Ac-FL-261 for solid tumors) once approved. Company explicitly states it aims to own the entire value chain for radiopharmaceutical research & development, production & commercialization. Currently no products are approved or generating commercial sales revenue.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Full-Life Technologies is a fully integrated global radiotherapeutics company that develops, manufactures, and commercializes Radionuclide Drug Conjugate (RDC) medicines for cancer therapy. Its proprietary UniRDC™ discovery platform uses Clear-X™ linker and Res-X™ modification technologies to generate RDC candidates across small molecule, cyclic peptide, and nanobody modalities. The pipeline includes clinical-stage 225Ac-FL-020 (PSMA), out-licensed FL-091 (NTSR1, now SKL35501/SKL35502), and preclinical candidates FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3), supported by an in-house GMP radiopharmaceutical manufacturing facility in Gembloux, Belgium.

Product overview

Full-Life Technologies is a clinical-stage, fully integrated global radiotherapeutics company with operations in Belgium, Germany and China. Its offering is a platform-plus-modules architecture anchored on the proprietary UniRDC™ discovery platform, which uses the Clear-X™ linker technology and Res-X™ modification methods to generate Radionuclide Drug Conjugate (RDC) candidates spanning small molecules, cyclic peptides, and nanobodies. The pipeline produced from UniRDC™ includes the clinical-stage PSMA-targeting 225Ac-FL-020, the licensed NTSR1 program FL-091 (now SKL35501/SKL35502 at SK Biopharmaceuticals), and preclinical assets FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3). The platform is paired with a GMP-compliant radiopharmaceutical manufacturing facility under construction in Gembloux, Belgium, a global radioisotope production and logistics capability, and a partnering program offering strategic collaborations, platform discovery partnerships, and in-licensing. Together the UniRDC™ discovery engine, pipeline of RDC product candidates and integrated manufacturing/logistics form an end-to-end radiopharmaceutical value chain.

Differentiator

Problem solved

Functional benefit

Brands

• UniRDC™: Proprietary discovery platform that rationalizes and accelerates the discovery process of RDC (Radionuclide Drug Conjugate) drug candidates, enabling a discovery timeline of 18 months or less from a target to an RDC development candidate.
• Clear-X™
• Res-X™

Products and services

• 225Ac-FL-020 (PSMA RDC)
• FL-091 (NTSR1 RDC; out-licensed as SKL35501)
• FL-031 (SSTR2 RDC)
• FL-261 (c-MET RDC)
• FL-801 (B7H3 nanobody RDC)
• FL-802 (B7H3 RDC)
• UniRDC™ Discovery Platform

Quantifiable outcome

• UniRDC™ platform enables discovery-to-development-candidate timeline of 18 months or less (with human biodistribution data)
• +6 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• SK BiopharmaceuticalsflagshipOEM/ Whitelabel/ Licensing Partner · 1 July 2024In July 2024, Full-Life entered an exclusive worldwide licensing agreement with SK Biopharmaceuticals for FL-091 (renamed SKL35501 therapeutic and SKL35502 imaging agent) — a NTSR1-targeting alpha-emitter RDC program. Total deal value of US$571.5 million including upfront payment, development and commercial milestones, and royalties. SK Biopharmaceuticals obtained right of first negotiation for other selected RDC programs from Full-Life. Therapeutic candidate SKL35501 received FDA IND clearance in January 2026 (approximately 18 months after in-licensing), validating Full-Life's UniRDC™ platform.
• Eckert & ZieglercoreStrategic or Co-development Partner · 1 January 2024Entered an Actinium-225 (Ac-225) supply agreement with Full-Life Technologies (January 2024) for next generation radiopharmaceuticals. Eckert & Ziegler (ISIN DE0005659700, SDAX-listed) is a German radioisotope and radiopharmaceutical supplier. The agreement supports Full-Life's clinical-stage and pipeline programs targeting the global Ac-225 supply bottleneck.
• Focus-X TherapeuticsflagshipOthers · 1 November 2022Full-Life acquired New Jersey-based Focus-X Therapeutics in November 2022 (close expected Q1 2023) for an upfront payment plus potential development, regulatory and sales-based milestones of up to US$245 million, plus royalties on commercial sales. Acquisition added two development-ready compounds (a PSMA-targeted peptide for mCRPC and a NTSR1-targeted peptide for pancreatic cancer), a proprietary peptide engineering discovery platform, and six earlier-stage programs. Focus-X co-founder Fa Liu became Full-Life's Chief Scientific Officer.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Novartis: Novartis owns Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), the two approved radioligand therapies addressing Full-Life's lead PSMA and adjacent SSTR2 indications. Acquired Advanced Accelerator Applications in 2018 and is investing heavily in next-generation alpha-emitter RDCs, making it the dominant incumbent against which Full-Life's 225Ac-FL-020 must compete.
• Lantheus Holdings: Lantheus is a US radiopharmaceutical specialist commercializing diagnostic radiopharmaceuticals (e.g., PYLARIFY for PSMA imaging) and developing PSMA-targeted therapeutics. Acquired Point Biopharma in 2024 to add radioligand therapy capabilities, making it a direct commercial-scale competitor in PSMA.
• Bayer: Bayer markets Xofigo (radium-223) for prostate cancer and acquired Algeta for alpha-emitter therapy. Bayer's broader pharma pipeline and global oncology commercial footprint make it a competitor in alpha-emitter oncology, though its radiopharma focus is narrower than Full-Life's RDC platform.
• Eli Lilly (RayzeBio / Point Biopharma): Eli Lilly acquired RayzeBio (actinium-225 RDC platform) in 2024 for $8.7B and Point Biopharma (PSMA-targeted therapy) in 2023, consolidating two leading radiopharmaceutical competitors. Lilly's scale, oncology commercial reach, and big-pharma R&D make it one of Full-Life's most consequential competitors in alpha-emitter RDCs and PSMA.

Direct peers

• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with approved PSMA-PET imaging agent Illuccix and an emerging therapeutic pipeline, including alpha-emitter programs. Directly comparable to Full-Life as a radiopharma company operating across PSMA imaging and therapy with both diagnostic and therapeutic assets.
• ITM Isotope Technologies Munich SE: ITM is a German-based radiopharmaceutical company producing medical radioisotopes and developing targeted radionuclide therapies, including Lu-177 and Ac-225-based candidates. Direct competitor in alpha-emitter RDC development with proprietary isotope production capabilities analogous to Full-Life's Belgium facility.
• Ariceum Therapeutics: Ariceum is a private clinical-stage radiopharmaceutical company developing targeted radionuclide therapies (e.g., satoreotide for SSTR2-expressing tumors). Direct comparable to Full-Life in pipeline breadth across multiple solid tumor targets using proprietary peptide-based RDC technology.

Emerging players

• Aktis Oncology: Aktis Oncology is a US-based clinical-stage radiopharmaceutical company developing alpha-emitter RDC candidates against validated solid tumor targets, including NTSR1. Direct emerging competitor with overlapping modality (Ac-225 conjugates) and some shared target space with Full-Life's pipeline.
• Convergent Therapeutics: Convergent is developing CLR 131 (radiopharmaceutical) and other targeted radiotherapeutics for prostate cancer. An emerging player in PSMA radioligand therapy overlapping with Full-Life's 225Ac-FL-020 program, focused on next-generation radioconjugates.

Others

• Eckert & Ziegler: Eckert & Ziegler is a SDAX-listed German radioisotope and radiopharmaceutical supplier that signed an Ac-225 supply agreement with Full-Life in January 2024. Functions as both a strategic supplier and ecosystem participant in the alpha-emitter radiopharmaceutical space, with adjacent (not directly competing) business in isotope production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/full-life-technologies

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Full-Life Technologies